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Abstract
Background: Determining physicians’ awareness about alpha-1 antitrypsin (AAT) deficiency (AATD) may help to
explain the discrepancy between the observed and expected number of patients diagnosed with this disease.
This study was designed to assess the opinions on knowledge, practice pattern and attitude regarding AATD
among physicians in Spain and Portugal.
Methods: An online anonymous survey was performed on pulmonologists (n = 100), internal medicine specialists
(IMS) (n = 100) and primary care physicians (PCP) (n = 176). Of the total number of physicians, 221 were from Spain,
and 155 were from Portugal. Physicians answered 21 questions related to their personal and professional profile,
knowledge regarding AATD and chronic obstructive pulmonary disease (COPD), performance and attitude about
AATD, and use of augmentation therapy. Responses were ranked on a 4-point scale indicating the level of
agreement. In addition, some of the responses were rated as either “low” or “high” indicating the level of
knowledge the respondent felt he/she possessed.
Results: Only 14 % of physicians reported to “know very well” about AATD (3.3 [SD 0.6] for pulmonologists vs. 2.64
[SD 0.60] for IMS and 2.48 [SD 0.71] for PCP; p < 0.001). Only 45.2 % of physicians correctly answered “<50 mg/dL”
as the threshold value of serum AAT to be considered severe AATD (55.0 % of pulmonologists vs. 47.0 % of IMS
and 38.6 % of PCP; p = 0.001). Choice of the correct answer did not agree with those physicians self-declaring a
high level of AATD knowledge (51.2 %). A total of 43.9 % of physicians correctly identified all diseases or conditions
in a list associated or not with AATD. A similar trend was detected when identifying which conditions would be
responsive to augmentation therapy (<50 %). Only 15.8 % of specialists performed AATD testing in all patients with
COPD (27.0 % pulmonologists, 12.6 % PCP; p = 0.001).
Conclusion: The results suggest that a knowledge gap may be contributing to the underdiagnosis of AATD.
Physicians in Spain and Portugal showed a marked lack of awareness of their shortcomings in knowledge about
AATD, and in general did not follow guidelines and recommendations for AATD testing.
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Background
Alpha-1 antitrypsin (AAT) deficiency (AATD) is a com-
mon but underdiagnosed human hereditary disorder
characterized by impaired or defective production of
AAT protein in the liver [1], which mainly results in
compromised pulmonary protection. In AATD, protease
inhibitor (PI)-deficient alleles (primarily PI*Z and PI*S)
are inherited from the AAT gene locus instead of the
normal allele (PI*M). In Europe, there are differences in
gene frequencies between geographic regions [2] and the
PI*S allele is more common than the PI*Z allele in west-
ern countries, such as Spain and Portugal [3].
Balanced protease-antiprotease function is maintained
mainly by AAT in the healthy lung through inhibition of
human neutrophil elastase [4, 5], an enzyme that degrades
basement membrane components of lung epithelium and
connective tissue, activates other proteinase proenzymes,
and is chemoattractant for inflammation cells. AAT excess
can lead to destruction of alveolar walls [6] and is associ-
ated with increased risk of early-onset pulmonary emphy-
sema as well as liver disease due to accumulation of
misfolded protein in hepatocytes [7].
In addition to liver disease, panniculitis and vasculitis
also have been associated with AATD. Adult-onset
AATD-associated liver disease manifests as cirrhosis and
fibrosis [8]. Panniculitis occurs in approximately 1 of 1000
individuals with AATD [9, 10]. AATD is associated with
the risk of C-ANCA-positive vasculitis, such as polyangii-
tis with granulomatosis [11].
Normal AAT concentration measured by nephelometry
in serum is 120–220 mg/dL [12]. Guidelines for the diagno-
sis and treatment of AATD determine the protective
threshold level of serum AAT at 50 mg/mL [10–14]. Rec-
ommendations and guidelines of healthcare institutions,
such as the World Health Organization, The Spanish
Society of Pneumology and Thoracic Surgery (SEPAR) and
the American and European Thoracic/Respiratory Societies
(ATS/ERS), indicate that all chronic obstructive pulmonary
disease (COPD) subjects and adults with nonreversible
asthma should be tested for AATD at least once during
their lifetime [10, 14, 15]. In that regard, the Spanish Regis-
try of Patients with AATD (REDAAT) has developed a
AATD free-cost detection program using dried blood spots
that is available for physicians.
However, even with the availability of AATD screening
and detection programs [16–23], the number of patients
diagnosed with AATD is much less than expected accord-
ing to epidemiologic studies [24, 25], which suggests that
adherence to recommendations is lacking. Understanding
the level of knowledge physicians have about all aspects of
AATD is crucial to determining the possible reasons why
such a delay in the diagnosis of AATD still exists [26].
This study explored the awareness of physicians in
Spain and Portugal towards the diagnosis of AATD. The
possible relationship between the results of the survey
and the underdiagnosis of AATD is discussed.
Methods
Study design
This cross-sectional, observational study was conducted
in July and August of 2014 by means of an online survey.
This study did not require institutional protocol approvals
or special consents because the nature of the survey was
anonymous. The target physician population consisted of
pulmonologists, internal medicine specialists (IMS) and
primary care physicians PCP) in Spain and Portugal who
treat at least five patients with COPD per month. A total
of 4714 physicians (2700 from Spain and 1414 from
Portugal) were invited to participate in the survey (link
accessed) who were randomly identified from an inter-
national medical marketing research database according
to geographic distribution and proportion of each spe-
cialty. Those who accepted the invitation and responded
to the survey were verified to meet the study requirements
and de-identified to guarantee anonymity.
Study objectives
The main objective of this study was to assess the level of
knowledge and practice pattern regarding AATD among
physicians in Spain and Portugal. Secondary objectives
were to explore their practice pattern and attitude regard-
ing AATD based on clinical specialty (pulmonologists,
IMS and PCP).
Characteristics of the questionnaire and survey data-
handling
Physicians answered a 15-minute, 21–question survey
about their personal and professional profile (e.g., age, sex,
location, specialty, experience) and their knowledge re-
garding AATD and COPD (e.g., threshold value of serum
AAT, diseases or conditions associated with AATD, cri-
teria for the indication of AAT augmentation therapy).
The survey also collected information on physician’s prac-
tice pattern and attitude about AATD (e.g., testing prac-
tice, communication with patient and laboratory) and
their use of augmentation therapy. Responses were rated
according to a numerical Likert scale, where “none at all”/
“totally disagree” = 1, “a little”/“somewhat disagree” = 2,
“average”/“somewhat agree” = 3, and “very well”/“totally
agree” = 4. Some responses to knowledge-based questions
(e.g, “How much you think that you know about AATD?”)
were rated in 2 categories of knowledge for secondary
analysis (low level: to know “none at all” or “a little”; high
level: to know “average” or “very well”). This questionnaire
was similar to a previously published survey performed on
German and Italian physicians [26] with the addition of a
few questions related to knowledge and opinions about
AATD. The survey data were analyzed based on the
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country in which the physician practiced and/or his/her
clinical specialty. The questionnaire is available as an ap-
pendix to this report.
Statistical analysis
Quantitative variables are shown as mean and standard
deviation (SD) or median and interquartile range (IQR). In
the case of qualitative variables, frequency and percentages
were determined. Differences between specialties and coun-
try were determined using chi-square test (or Fisher’s test
when the expected frequencies <5) for qualitative variables,
and by ANOVA test or T Student test for quantitative vari-
ables. In all cases, statistically significant differences were
considered p < 0.05. Statistical analysis was performed using
the SPSS 19.0 Software (Chicago, IL, USA).
Results
Physician profile
A total of 376 physicians participated in the study, 221
(58.8 %) from Spain and 155 (41.2 %) from Portugal. Survey
participants included 100 pulmonologists (26.6 %; 60 in
Spain and 40 in Portugal), 176 PCP (46.8 %; 101 in Spain
and 75 in Portugal) and 100 IMS (26.6 %; 60 in Spain and
40 in Portugal). Mean age of the surveyed physicians was
46.7 (SD 9.6) years, and 63 % were male. Physicians repre-
sented a mean professional experience of 18.7 (SD 8.9)
years and treated a median of 40 (IQR = 20–90) patients
with COPD per month. No differences were observed be-
tween countries in these variables (data not shown).
Self-declared knowledge and opinions about AATD and
other respiratory diseases
The level of knowledge regarding AATD was lower com-
pared with COPD on the 4-point scale (2.75 [SD 0.75] vs.
3.7 [SD 0.5], respectively; p = 0.001). Only 14 % of physi-
cians reported to know “very well” about AATD. Pulmonol-
ogists (3.3 [SD 0.6]) declared to have a higher level of
knowledge in AATD than IMS (2.64 [SD 0.60]) and PCP
(2.48 [SD 0.71]) (p < 0.001). Figure 1 shows the degree of
knowledge by percentages using the Likert scale according
to specialists. For COPD, 65.2 % of physicians declared to
know “very well”. In particular, pulmonologists were the
specialists who declared to better know about COPD (3.86
[SD 0.38] for pulmonologists vs. 3.73 [SD 0.45] for IMS and
3.48 [SD 0.50] for PCP; p < 0.001).
The main source of information for AAT deficiency
was textbooks (79.7 %), followed by scientific articles
(73.5 %). Other sources of information used by almost
half of the physicians were clinical guidelines (46.8 %),
scientific congresses (45.4 %) and advice from experts
and colleagues (43.7 %).
Knowledge about AATD was evaluated by three ques-
tions. In the first question, only 45.2 % of physicians cor-
rectly answered “<50 mg/dL” as the threshold value of
serum AAT to be considered severe AATD. Pulmonolo-
gists had the highest rate of choosing the correct answer
compared to physicians from other specialties (55.0 %
for pulmonologists vs. 47.0 % of IMS and 38.6 % of PCP;
p = 0.001). When these results were compared against
the self-declared knowledge about AATD, only 51.2 % of
those who declared to know “average” or “very well”
about AATD correctly chose “<50 mg/dL.” This percent-
age was higher than that observed in those who declared
to know “a little” or “none at all” (33.8 %; p = 0.001).
In the second question, physicians were asked to pick
from a list of 6 diseases or conditions which ones can be
associated with AATD. “Hepatic cirrhosis” was correctly
chosen by 72.8 % (PCP), 73 % (IMS) and 93 % (pulmonolo-
gists) of physicians as being a disease associated with
AATD, while less than 44 % of all physicians correctly iden-
tified “panniculitis” and “vasculitis”. Diseases not associated
with AATD, such as “heart disease” and “arterial hyperten-
sion” were selected by 8.5 and 19.9 % of physicians, respect-
ively. A total of 43.9 % of physicians identified the three
Fig. 1 Self-reported level of knowledge about alpha-1 antitrypsin deficiency (p < 0.001 among groups) (PUL: pulmonologists, PCP: primary care
physicians, IMS: internal medicine specialists)
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correct answers and the two incorrect answers, with no sta-
tistically significant differences among specialties (46.0 % of
pulmonologists, 49.0 % of IMS and 39.8 % of PCP, p =
0.35). No differences were observed when comparisons
were made with respect to the degree of self-declared
knowledge (p = 0.670).
The third question about AATD knowledge referred to
the criteria for the indication of AAT augmentation ther-
apy. Only 18 physicians (4.8 %) identified the correct an-
swers (“older than 18 years of age,” “severe AATD,”
“emphysema,” “FEV1 36–60 %,” and “not active smoker”)
and identified “liver disease” as the incorrect answer. No
differences were observed regarding the degree of self-
declared knowledge of AATD (p = 0.102). Physicians in
Portugal showed a lower level of knowledge about criteria
for augmentation therapy than did physicians in Spain.
Detailed information according to specialty and country is
shown in Table 1.
When physicians were asked about their opinion on
the efficacy of AAT augmentation therapy for severe
AATD, 44.9 % believed that therapy “slows the emphy-
sema progression,” and there were differences among
specialists (63.0 % of pulmonologists vs. 42.0 % of IMS
and 36.4 % of PCP; p = 0.001). Lower percentages were
observed for other settings Fig. 2.
Routine AATD testing performance and management
More than 80 % of physicians declared that they test
family members of AATD patients and young COPD pa-
tients (<45 years of age) (Fig. 3). However, only 15.8 % of
physicians commonly tested for AATD in all patients
with COPD (27.0 % of pulmonologists, 12.6 % of PCP
and 4 % of IMS; p = 0.001). Physicians with a high degree
of self-declared knowledge performed AATD testing in
all COPD patients more frequently than physicians with
a lower degree (p < 0.05). The most common number of
monthly requests for AATD was between 1 and 5 tests
(73.6 % of physicians), regardless of specialty.
Characteristics in frequency and number of tests by
country are shown in Table 2. Physicians who reported
not performing testing for AAT deficiency regularly
cited referrals to another specialist (39.9 %) and the high
cost of testing (39.0 %) as the main reasons for not test-
ing, with some significant differences among specialties
and country, as shown in Table 3. Up to 31.9 % of all
physicians declared to have never treated any AATD pa-
tient with augmentation therapy.
Physician’s attitude and communication
Among the 265 physicians (70.5 %) who declared to regu-
larly or occasionally test for AATD, 45.2 % totally agreed
with the usefulness of the information provided by the la-
boratory, while 27.0 % totally agreed that the laboratory
provided educational material about the implication of the
test results for the patient. Pulmonologists were those
most satisfied with the clarity of communication with the
Table 1 Responses to the question about criteria for the indication of augmentation therapy for alpha-1 antitrypsin deficiency (n, %)
Spain Portugal P
value
PUL IMS PCP P
value
Total
N = 221 N = 155 N = 100 N = 100 N = 176 N = 376
Severe AATD 190 (86.0) 103 (66.5) <0.001 96 (96.0) 77 (77.0) 120 (68.2) <0.001 293 (77.9.0)
Emphysema 146 (66.1) 69 (44.5) 0.001 71 (71.0) 55 (55.0) 89 (50.6) 0.004 215 (57.2)
FEV1 99 (44.0) 54 (34.8) NS 63 (63.0) 36 (36.0) 54 (30.7) <0.001 153 (40.7)
-<=35 % 28 (12.7) 17 (11.0) NS 20 (20.0) 12 (12.0) 13 (7.4) 0.008 45 (12.0)
-36–60 % 71 (32.1) 25 (16.1) 0.001 42 (42.0) 18 (18.0) 36 (20.6) <0.001 96 (25.5)
-61–80 % 7 (7.7) 16 (10.3) NS 17 (17.0) 8 (8.0) 8 (4.5) <0.001 33 (8.7)
Non smoker 99 (44.8) 56 (36.1) NS 72 (72.0) 33 (33.0) 50 (28.1) <0.001 155 (41.2)
Liver disease 80 (36.2) 42 (27.1) NS 33 (33.0) 40 (40.0) 49 (27.1) NS 122 (32.4)
Age >18 years 65 (29.4) 46 (29.7) NS 46 (46.0) 23 (23.0) 42 (23.9) <0.001 111 (29.5)
PUL pulmonologists, IMS internal medicine specialists, PCP primary care physicians, AATD Alpha-1 antitrypsin deficiency, NS nonsignificant
Fig. 2 Conditions in which augmentation therapy with alpha-1
antitrypsin is effective according to physicians (*P = 0.001; **P =
0.002) (PUL: pulmonologists, PCP: primary care physicians, IMS:
internal medicine specialists)
Esquinas et al. BMC Pulmonary Medicine  (2016) 16:64 Page 4 of 7
laboratory (57.7 %) compared to IMS and PCP who were
less satisfied (32.1 and 25.2 %, respectively; p = 0.001).
Regarding communication with patient, only 16.6 % of
all physicians clearly affirmed that they had educational
materials about AATD available for patients and fam-
ilies. While 71.1 % of pulmonologists “totally agreed”
with the clarity of communication with the patient, only
44.4 % of PCP did (p = 0.001). In addition, 12.5 % of
physicians “totally agreed” with feeling uneasiness due to
the genetic nature of the disease, and 11.3 % felt unsure
about giving advices on prognosis, life style and
treatments.
Discussion
The results of this study performed by means of an
online survey on physicians in Spain and Portugal
indicate not only a poor knowledge about AATD in
this target group, even in lung specialists, but also a
pronounced lack of awareness of such shortcomings.
It is possible that such knowledge gap contributes to
the low rate of AAT testing done by physicians, par-
ticularly PCP. AATD testing is recommended for all
COPD patients regardless of age or smoking history.
Discrepancy between the observed and expected
number of patients diagnosed with AATD has been
repeatedly reported [16, 18, 24]. Insights on the phy-
sicians’ awareness, knowledge, understanding, atti-
tude and practice pattern in AATD may provide a
hint to explain the delay in the diagnosis of AATD.
As expected, pulmonologists were the specialists who
mostly self-declared to know “very well” about both
AATD and COPD the most, followed by IMS and PCP.
However, the knowledge declared about AATD was sig-
nificantly lower than COPD. This profile is in agreement
with that reported by Greulich and coworkers for a simi-
lar study conducted in Germany and Italy [26]. When all
of the physicians were considered, only 14 % declared to
know “very well” about AATD. This value seems low,
although it is difficult to determine the percentage level
that one would consider such knowledge as acceptable.
Surprisingly, only 51.2 % of all physicians who self-
declared to know “very well” about AATD identified
correctly the “50 mg AAT/dL” in serum as the upper
limit for severe AATD. This percentage was similar
when only pulmonologists (55.0 %) and IMS (47.0 %)
were considered. Similarly, less than half of all physicians
were able to correctly identify in a list the diseases or
conditions that can be associated with AATD and those
that are not. Even lower knowledge was observed when
less than 5 % of all physicians identified all the correct
and incorrect criteria for the indication of AAT augmen-
tation therapy. These results confirm that there is a low
degree of knowledge about AATD in the physician spe-
cialties surveyed, even among those pulmonologists who
believed to know “a lot” about AATD. Thus, AATD may
be overlooked by physicians, particularly PCP, who de-
clared even less knowledge about AATD, in accordance
with other survey studies [26, 27].
In addition to the insufficient knowledge about AATD,
and probably related to it, not all AAT determinations
that would be desirable were performed. Despite recom-
mendations and guidelines of healthcare institutions
Fig. 3 Clinical profile of patients tested by physicians for alpha-1
antitrypsin deficiency (*P = 0.010; **P = 0.001) (PUL: pulmonologists,
PCP: primary care physicians, IMS: internal medicine specialists; AATD:
Alpha-1 antitrypsin deficiency; COPD: Chronic Obstructive Pulmonary
Disease; BE: bronchiectasis)
Table 2 Diagnosis and management of alpha-1 antitrypsin
deficiency by country (n, %)
Spain Portugal Total sample
Frequency of request AATD testing N = 221 N = 155 N = 376
Yes, regularly 51 (23.1) 17 (11) 68 (18.1)
Yes, occasionally 118 (53.4) 79 (51) 197 (52.4)
No 52 (23.5) 59 (38.1) 111 (29.5)
Number of test per month N = 169 N = 96 N = 265
From physicians currently testing
None 12 (7.1) 17 (17.7) 29 (10.9)
1–5 121 (71.6) 74 (77.1) 195 (73.6)
6–10 29 (17.2) 4 (4.2) 33 (12.5)
>10 7 (4.1) 1 (1) 8 (3)
Profile of patients tested N = 169 N = 96 N = 265
From physicians currently testing
All patients with COPD 30 (17.8) 12 (12.5) 42 (15.8)
COPD <45 years 140 (82.8) 83 (86.5) 223 (84.2)
Relatives AATD patients 144 (85.2) 81 (84,4) 225 (84.9)
Asthma 25 (14.8) 14 (14.1) 39 (14.7)
Bronchiectasis 89 (52.7) 45 (46.9) 134 (50.6)
Other conditions 13 (7.7) 13 (13.5) 26 (9.8)
COPD chronic obstructive pulmonary disease, AATD alpha-1
antitrypsin deficiency
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[10–15], only 4 % (IMS) to 27 % (pulmonologists) of
physicians in Spain and Portugal performed AATD test-
ing in all patients with COPD, although many tested
young COPD patients and relatives of AATD patients.
Reasons cited for not testing patients as well as percent-
ages observed were similar to those described in
Germany and Italy [26].
Since primary care is the central form of health access
for patients with COPD, there is concern on how to en-
gage PCP to reduce the underdiagnosis of AATD [28].
In our study, PCP felt the least comfortable with com-
municating to both the analysis laboratory and the
patient.
In Spain, strategies such a detection program of AATD
in COPD patients using dried blood spot have been per-
formed. Results showed a feasible program at a reason-
able cost per case detected (17). Pilot studies, such as
the IDDEA web tool, aimed to coordinate the flow of
data between the PCP, the analysis laboratory, and the
pulmonologist have been developed for the screening
and detection of AATD in the primary care setting [23].
Educational materials were also provided to the PCP to
increase their awareness about AAT. However, our re-
sults suggest that before providing adequate diagnostic
tools to physicians, particularly family doctors, there is
still significant room for improvement in physician edu-
cation and knowledge related to AATD. Further strat-
egies such as inclusion of AAT testing in COPD
guidelines, national screening programs with simpler
testing approaches and an increase in physician educa-
tion about AATD should help to improve in the AATD
diagnosis.
Physician population surveyed in this study was con-
sidered balanced in account of the socio-demographic
weight of the represented countries, practice setting and
specialty. Although Spain and Portugal can be deemed
more socio-culturally similar than Italy and Germany
was in the study by Greulich and coworkers [26], some
differences were found out. Explanation may lie on facts
such as the unavailability of specific guidelines and a
reference laboratory in Portugal. Although Portuguese
professionals may use the ATS/ERS [10] or even the
Spanish guidelines [13, 14] if necessary, that may repre-
sent a serious limitation.
Shortcomings and limitations typically associated with
observational studies can affect this survey-based assess-
ment performed on physicians in Spain and Portugal.
Moreover, the survey was anonymous, gathered only the
profile of those who accepted to participate, and focused
on opinions and declarations about their own practice
and self-declared knowledge about diagnosis and treat-
ment of AATD, rather than based in daily routine quan-
tifications. It is known that self-evaluation can be
subjected to bias [29]. In fact, our results would be in
agreement with the tendency to overestimate one’s
knowledge and abilities.
Conclusions
We found insufficient knowledge and unsatisfactory
practice about AATD of physicians at all levels, from
PCP to IMS and pulmonologists, which may be linked
to insufficient adherence of the guidelines and recom-
mendations for testing all COPD patients. The results of
this study are consistent with the generalized underscre-
ening and underdiagnosis of AATD.
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Table 3 Physician’s reasons not to perform alpha-1 antitrypsin deficiency test. Data show totally agreement in each question (n, %)
Spain Portugal P
value
PUL IMS PCP P
value
Total
N = 170 N = 138 N = 55 N = 91 N = 162 N = 308
Not available treatment 11 (6.5) 13 (9.4) NS 6 (10.9) 10 (11.0) 8 (4.9) NS 24 (7.8)
Not having time 20 (11.8) 11 (8.0) NS 9 (16.0) 4 (4.0) 18 (11.0) 0.016 31 (10.1)
High economic cost 77 (45.3) 43 (31.2) 0.011 22 (40.0) 45 (49.5) 53 (32.7) 0.032 120 (39.0)
Too long to receive results 27 (15.9) 10 (7.2) 0.020 12 (21.8) 11 (12.0) 14 (8.6) 0.034 37 (12.0)
Not visiting any patient with AATD 10 (5.9) 39 (28.3) <0.001 5 (9.0) 17 (18.0) 27 (16.7) NS 49 (15.9)
Referred to other specialist 59 (34.7) 64 (46.4) 0.038 11 (20.0) 28 (30.0) 84 (52.0) 0.001 123 (39.9)
Any positive determination 23 (13.5) 2 (1.4) <0.001 6 (10.0) 11 (12.0) 8 (5.0) NS 25 (8.1)
Unclear interpretation of results 14 (8.2) 9 (6.5) NS 4 (7.0) 6 (6.0) 13 (8.0) NS 23 (7.5)
Other 31 (18.2) 25 (18.1) NS 14 (25.5) 18 (19.0) 24 (14.8) NS 56 (18.2)
PUL pulmonologists, IMS internal medicine specialists, PCP primary care physicians, AATD alpha-1 antitrypsin deficiency, NS nonsignificant
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